{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:45Z","timestamp":1793747085639,"version":"4.6.1"},"reference-count":11,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC) remains associated with significant morbidity despite therapeutic advances. The impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on UC disease activity is not well defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study using electronic health records from a single tertiary academic health system (2022-2024). Adults with UC initiating liraglutide or semaglutide for metabolic indications and maintained on therapy \u2265 12\u2009weeks were included. A 1:1 matched cohort of UC patients not receiving GLP-1 RAs served as controls. The primary outcome was symptomatic remission at 12\u2009weeks (partial Mayo \u2264 2 with rectal bleeding subscore 0). Multivariable logistic regression assessed adjusted odds of remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 150 GLP-1 RA patients were matched to 150 controls with comparable baseline characteristics. GLP-1 RA use was associated with higher remission rates at 4\u2009weeks (34.7% vs 15.3%, P\u2009=\u2009.001), 8\u2009weeks (54.7% vs 18.0%, P\u2009&amp;lt;\u2009.001), and 12\u2009weeks (66.7% vs 25.3%, P\u2009&amp;lt;\u2009.001). Mean partial Mayo scores improved from 5.8 at baseline to 2.1 at 12\u2009weeks in the GLP-1 RA group vs 4.6 in controls (P\u2009&amp;lt;\u2009.01). GLP-1 RA use remained independently associated with remission (adjusted OR 5.90, 95% CI 3.52-9.86; P\u2009&amp;lt;\u2009.001). Weight loss was not associated with remission. Semaglutide demonstrated higher remission rates than liraglutide (72.5% vs 60%; OR 1.77, P\u2009=\u2009.04). Endoscopic outcomes in a subset showed higher remission (58% vs 38%) and improvement (69% vs 47%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1 RA therapy was associated with significantly improved UC disease activity and higher remission rates compared to matched controls, with a modest advantage observed for semaglutide. These findings support a potential adjunctive role for GLP-1 RAs in UC, particularly in patients with metabolic comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag167","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:23:51Z","timestamp":1786706631000},"source":"Crossref","is-referenced-by-count":4,"title":["GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2734-4460","authenticated-orcid":false,"given":"Budoor","family":"Alqinai","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, West Virginia University , Morgantown, WV,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Gayam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, West Virginia University , Morgantown, WV,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hadam-Veverka","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, West Virginia University , Morgantown, WV,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2026082109334335200_izag167-B1","first-page":"100","article-title":"Efficacy, safety, and metabolic outcomes of GLP-1 receptor agonists in inflammatory bowel disease: a systematic review","volume":"61","author":"Maracle","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026082109334335200_izag167-B2","doi-asserted-by":"publisher","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026082109334335200_izag167-B3","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1097\/MIB.0000000000000847","article-title":"GLP-1 induces barrier protective expression in Brunner\u2019s glands and regulates colonic inflammation","volume":"22","author":"Bang-Berthelsen","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026082109334335200_izag167-B4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1 receptor agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1 receptor","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"2026082109334335200_izag167-B5","doi-asserted-by":"publisher","first-page":"8044","DOI":"10.18632\/aging.204953","article-title":"The alleviating effect and mechanism of GLP-1 on ulcerative colitis","volume":"15","author":"Wang","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"2026082109334335200_izag167-B6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/biomedicines9040383","article-title":"GLP-1 and intestinal diseases","volume":"9","author":"Hunt","year":"2021","journal-title":"Biomedicines"},{"key":"2026082109334335200_izag167-B7","doi-asserted-by":"publisher","first-page":"100979","DOI":"10.1016\/j.eclinm.2021.100979","article-title":"GLP-1 based therapies and disease course of inflammatory bowel disease","volume":"37","author":"Villumsen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2026082109334335200_izag167-B8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.18138","article-title":"Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease","volume":"60","author":"Desai","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026082109334335200_izag167-B9","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1007\/s10620-025-08964-6","article-title":"Tolerability and effectiveness of glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease","volume":"70","author":"Clarke","year":"2025","journal-title":"Dig Dis Sci"},{"key":"2026082109334335200_izag167-B10","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.14309\/ajg.0000000000003208","article-title":"Safety and effectiveness of glucagon-like peptide-1 receptor agonists in inflammatory bowel disease","volume":"120","author":"Anderson","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026082109334335200_izag167-B11","first-page":"913","article-title":"Glucagon-like peptide-1 receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential","volume":"19","author":"Fotheringham","year":"2025","journal-title":"J Crohns Colitis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag167\/70754804\/izag167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag167\/70754804\/izag167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:33:47Z","timestamp":1787319227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag167\/8767722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":11,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag167","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"izag167"}}